2023 ASCO-GU前列腺癌研究进展快递  

Research progress in 2023 ASCO-GU prostate cancer

作　　者：晁正 王亚楠 葛越 周强[1] 熊泽众 马晟 张俊彪 李乐[1] 王志华[1] CHAO Zheng;WANG Yanan;GE Yue;ZHOU Qiang;XIONG Zezhong;MA Sheng;ZHANG Junbiao;LI Le;WANG Zhihua(Department of Urology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430300,China)

机构地区：[1]华中科技大学同济医学院附属同济医院泌尿外科,湖北武汉430300

出　　处：《现代泌尿外科杂志》2023年第6期536-540,共5页Journal of Modern Urology

摘　　要：2023年美国临床肿瘤学会泌尿男生殖系肿瘤研讨会报道的多项研究进展对临床选择前列腺癌治疗方案有重要指导意义。依据人群特性开展精准化的多联疗法已成为前列腺癌治疗的主流趋势,包括转移性激素敏感性前列腺癌中的三药联合治疗及转移性去势抵抗性前列腺癌中的多腺苷二磷酸核糖聚合酶抑制剂联合治疗。此外,核素治疗和放疗也受到较多关注。在非转移性去势抵抗性前列腺癌中,核素诊疗一体化具有巨大潜力。对于局限性前列腺癌,立体定向放疗则成为手术之外的优先选项。本文通过解析会上多项不同阶段前列腺癌的重磅研究,以期使更多前列腺癌患者在治疗中获益。The 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium unveiled numerous research advances which provide meaningful insights into the selection of treatment regimens of prostate cancer.Precision multi-treatment based on patients characteristics has become the predominant approach,including the use of a three-drug combination therapy for metastatic hormone-sensitive prostate cancer,and poly adenosine diphosphate ribose polymerase inhibitor therapy for metastatic castration-resistant prostate cancer.Nuclear medicine therapy and radiotherapy are also receiving significant attention.Integrated nuclear medicine diagnosis and therapy show immense potential for non-metastatic castration-resistant prostate cancer.Additionally,for localized prostate cancer,stereotactic body radiotherapy is a preferred alternative to surgery.This article sheds light on several key studies presented at the conference,focuses on prostate cancer treatment at different stages,and intends to enhance the therapeutic outcome for prostate cancer patients.

关 键 词：前列腺癌 国际会议 解读 治疗进展 

分 类 号：R737.25[医药卫生—肿瘤]